QR-1123

Phase 1/2Active

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

✓

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

Autosomal Dominant Retinitis Pigmentosa

Conditions

Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary, Retinal Dystrophies, Retinal Disease, Retinitis, Vision Tunnel, Vision Disorders

Trial Timeline

Oct 7, 2019 → Jun 7, 2022

NCT ID

NCT04123626

About QR-1123

QR-1123 is a phase 1/2 stage product being developed by ProQR for Autosomal Dominant Retinitis Pigmentosa. The current trial status is active. This product is registered under clinical trial identifier NCT04123626. Target conditions include Autosomal Dominant Retinitis Pigmentosa, Eye Diseases, Eye Diseases, Hereditary.

What happened to similar drugs?

1 of 5 similar drugs in Autosomal Dominant Retinitis Pigmentosa were approved

Approved (1) Terminated (2) Active (2)

✅Placebo + EverolimusNovartisApproved

🔄Everolimus + Calcineurin inhibitors maintenanceNovartisPhase 3

❌Bardoxolone methyl oral capsule + Placebo oral capsuleBiogenPhase 3

🔄Lanreotide + salineIpsenPhase 3

❌Lixivaptan + PlaceboCentessa PharmaceuticalsPhase 3

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT04123626	Phase 1/2	Active	Oct 7, 2019	Jun 7, 2022	Autosomal Dominant Retinitis Pigmentosa

Competing Products

19 competing products in Autosomal Dominant Retinitis Pigmentosa

See all competitors

Product	Company	Stage	Hype Score
ABBV-CLS-628 + Placebo	AbbVie	Phase 2	42
AZD1613 - Part A + Placebo - Part A + AZD1613 - Part B + Placebo - Part B	AstraZeneca	Phase 1	36
Placebo + Everolimus	Novartis	Approved	43
Octreotide + Placebo	Novartis	Phase 2/3	38
Everolimus + Calcineurin inhibitors maintenance	Novartis	Phase 3	40
Bosutinib + Bosutinib + Placebo	Pfizer	Phase 2	35
VX-407	Vertex Pharmaceuticals	Phase 2	42
VX-407 + LNG/EE + NGM/EE + NET/EE + DRSP/EE	Vertex Pharmaceuticals	Phase 1	33
VX-407 + Placebo + Midazolam + VX-407	Vertex Pharmaceuticals	Phase 1	29
VX-407 + Placebo	Vertex Pharmaceuticals	Phase 1	33
Tesevatinib	Sanofi	Phase 1/2	32
Tesevatinib + Placebo	Sanofi	Phase 2	35
Venglustat + Placebo	Sanofi	Phase 2/3	30
Bardoxolone methyl oral capsule + Placebo oral capsule	Biogen	Phase 3	29
Lanreotide + saline	Ipsen	Phase 3	37
KB105	Krystal Biotech	Phase 2	28
KB105	Krystal Biotech	Phase 1/2	25
Lixivaptan + Placebo	Centessa Pharmaceuticals	Phase 3	29
GLPG2737 + Placebo	Galapagos	Phase 2	21